RT Journal Article
SR Electronic
T1 The Effects of Eribulin on Breast Cancer Microenvironment Identified Using Eribulin-resistant Breast Cancer Cell Lines
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4031
OP 4041
DO 10.21873/anticanres.13559
VO 39
IS 8
A1 WATARU GOTO
A1 SHINICHIRO KASHIWAGI
A1 YUKA ASANO
A1 KOJI TAKADA
A1 KATSUYUKI TAKAHASHI
A1 HISAKAZU FUJITA
A1 TSUTOMU TAKASHIMA
A1 MASATSUNE SHIBUTANI
A1 RYOSUKE AMANO
A1 SHUHEI TOMITA
A1 KOSEI HIRAKAWA
A1 MASAICHI OHIRA
YR 2019
UL http://ar.iiarjournals.org/content/39/8/4031.abstract
AB Background/Aim: Eribulin is currently used to treat advanced and metastatic breast cancer in the clinical setting; however, its efficacy is inhibited by resistance acquisition in many cases. Thus, the present study established two eribulin-resistant breast-cancer cell lines, and used these to investigate the mechanisms that underly eribulin-resistance acquisition. Materials and Methods: Eribulin-resistant breast-cancer cell lines were generated by culturing MDA-MB-231 and MCF-7 cells with increasing concentrations of eribulin. Results: The eribulin-resistant cells acquired resistance to eribulin, as well as several other anticancer drugs. After eribulin treatment, the eribulin-resistant cell lines showed no morphological change, no increased expression of epithelial-cadherin, nor any significant alteration in cell-cycle distribution. In contrast, the expression levels of programmed death-ligand 1 were increased in the MCF-7/eribulin-resistant compared to MCF-7 cells. Conclusion: The herein developed eribulin-resistant cell lines acquired cross-resistance to various anticancer agents, and displayed resistance to eribulin-induced effects on microtubule function and epithelial-mesenchymal transition (EMT).